Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886146 | 0.91 | CNR1 (0.52) | CNR1CNR2SCN9ACHRM1 | |
| SCHEMBL4886166 | 0.91 | CNR1 (0.52) | CNR1CNR2SCN9ACHRM1 | |
| SCHEMBL4632440 | 0.87 | CNR1 (0.46) | CNR1CNR2CA1CA2RIPK1 | |
| SCHEMBL4599472 | 0.84 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL4796011 | 0.84 | CNR1 (0.36) | CNR1CNR2CA1CA2KLKB1 | |
| SCHEMBL4885390 | 0.83 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4894758 | 0.83 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4891882 | 0.83 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4637589 | 0.82 | CNR1 (0.69) | CNR1SCN9A | |
| SCHEMBL4890606 | 0.82 | CNR1 (0.61) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | claimed |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | CNR1, CNR2, HTR3C | CNR1 1/4885CNR2 2/4885SCN9A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.